Eintrag weiter verarbeiten
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib
Gespeichert in:
| Zeitschriftentitel: | Annals of Oncology |
|---|---|
| Personen und Körperschaften: | , |
| In: | Annals of Oncology, 30, 2019, S. iv105 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
Elsevier BV
|
| Schlagwörter: |
| author_facet |
Pan, L. Cai, X. Pan, L. Cai, X. |
|---|---|
| author |
Pan, L. Cai, X. |
| spellingShingle |
Pan, L. Cai, X. Annals of Oncology PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib Oncology Hematology |
| author_sort |
pan, l. |
| spelling |
Pan, L. Cai, X. 0923-7534 Elsevier BV Oncology Hematology http://dx.doi.org/10.1093/annonc/mdz155.384 PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib Annals of Oncology |
| doi_str_mv |
10.1093/annonc/mdz155.384 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9hbm5vbmMvbWR6MTU1LjM4NA |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9hbm5vbmMvbWR6MTU1LjM4NA |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
Elsevier BV, 2019 |
| imprint_str_mv |
Elsevier BV, 2019 |
| issn |
0923-7534 |
| issn_str_mv |
0923-7534 |
| language |
English |
| mega_collection |
Elsevier BV (CrossRef) |
| match_str |
pan2019pdl1inhibitorsvstargetedtherapyvstheircombinationassecondlinetreatmentinpatientswithadvancedhepatocellularcarcinomapreviouslytreatedwithsorafenib |
| publishDateSort |
2019 |
| publisher |
Elsevier BV |
| recordtype |
ai |
| record_format |
ai |
| series |
Annals of Oncology |
| source_id |
49 |
| title |
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_unstemmed |
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_full |
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_fullStr |
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_full_unstemmed |
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_short |
PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_sort |
pd-(l)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| topic |
Oncology Hematology |
| url |
http://dx.doi.org/10.1093/annonc/mdz155.384 |
| publishDate |
2019 |
| physical |
iv105 |
| description |
|
| container_start_page |
0 |
| container_title |
Annals of Oncology |
| container_volume |
30 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792324749782679557 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T11:54:39.301Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=PD-%28L%291+inhibitors+vs+targeted+therapy+vs+their+combination+as+second-line+treatment+in+patients+with+advanced+hepatocellular+carcinoma+previously+treated+with+sorafenib&rft.date=2019-07-01&genre=article&issn=0923-7534&volume=30&pages=iv105&jtitle=Annals+of+Oncology&atitle=PD-%28L%291+inhibitors+vs+targeted+therapy+vs+their+combination+as+second-line+treatment+in+patients+with+advanced+hepatocellular+carcinoma+previously+treated+with+sorafenib&aulast=Cai&aufirst=X.&rft_id=info%3Adoi%2F10.1093%2Fannonc%2Fmdz155.384&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792324749782679557 |
| author | Pan, L., Cai, X. |
| author_facet | Pan, L., Cai, X., Pan, L., Cai, X. |
| author_sort | pan, l. |
| container_start_page | 0 |
| container_title | Annals of Oncology |
| container_volume | 30 |
| description | |
| doi_str_mv | 10.1093/annonc/mdz155.384 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTA5My9hbm5vbmMvbWR6MTU1LjM4NA |
| imprint | Elsevier BV, 2019 |
| imprint_str_mv | Elsevier BV, 2019 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 0923-7534 |
| issn_str_mv | 0923-7534 |
| language | English |
| last_indexed | 2024-03-01T11:54:39.301Z |
| match_str | pan2019pdl1inhibitorsvstargetedtherapyvstheircombinationassecondlinetreatmentinpatientswithadvancedhepatocellularcarcinomapreviouslytreatedwithsorafenib |
| mega_collection | Elsevier BV (CrossRef) |
| physical | iv105 |
| publishDate | 2019 |
| publishDateSort | 2019 |
| publisher | Elsevier BV |
| record_format | ai |
| recordtype | ai |
| series | Annals of Oncology |
| source_id | 49 |
| spelling | Pan, L. Cai, X. 0923-7534 Elsevier BV Oncology Hematology http://dx.doi.org/10.1093/annonc/mdz155.384 PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib Annals of Oncology |
| spellingShingle | Pan, L., Cai, X., Annals of Oncology, PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib, Oncology, Hematology |
| title | PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_full | PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_fullStr | PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_full_unstemmed | PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_short | PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_sort | pd-(l)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| title_unstemmed | PD-(L)1 inhibitors vs targeted therapy vs their combination as second-line treatment in patients with advanced hepatocellular carcinoma previously treated with sorafenib |
| topic | Oncology, Hematology |
| url | http://dx.doi.org/10.1093/annonc/mdz155.384 |